All In Biotech

Drug Trial Radar · NCT02335944

Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.

A Phase Ib/II, Multicenter, Open-label Study of EGF816 in Combination With INC280 in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer.

Last checked: Nov 19, 2026Latest source record: Jun 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

177

Actual

Start

Jan 13, 2015

Primary completion

Nov 10, 2020

Study completion Nov 10, 2020

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jan 12, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) of nazartinib (EGF816) in combination with capmatinib (INC280) and to estimate the preliminary anti-tumor activity of nazartinib in combination with capmatinib in participants with advanced non-small cell lung cancer (NSCLC) with documented EGFR mutation.

Conditions

  • Non Small Cell Lung Cancer

Interventions

  • CapmatinibDrug

    In the Phase 1, capmatinib was administered orally, twice per day, at a dose of 200 mg or 400 mg, in fasted state. In the Phase II, participants received capmatinib at the RP2D (400 mg twice per day) in fasted state (Groups 1, 2 and 3) or fed state (Group 4). Participants in Phase II Group 5 were to start with capmatinib monotherapy (fasted or fed state) and then would have had the opportunity to continue with the combination of nazartinib and capmatinib (fasted or fed state).

  • NazartinibDrug

    In the Phase 1, nazartinib was administered orally, once a day, at a dose of 50 mg, 75 mg, 100 mg or 150 mg in fasted state. In the Phase II, participants received nazartinib at the RP2D (100 mg once daily) in fasted state (Groups 1, 2 and 3) or fed state (Group 4). Participants in Phase II Group 5 were to start with capmatinib monotherapy (fasted or fed state) and then would have had the opportunity to continue with the combination of nazartinib and capmatinib (fasted or fed state).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ib: Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Up to first 28 days of treatment
  2. Phase II Group 1, 2 and 3: Overall Response Rate (ORR) by Investigator's Assessment Per RECIST 1.1Time frame: Up to approximately 4 years
  3. Phase II Group 4: Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)Time frame: From start of treatment up to 30 days after last dose of study treatment, assessed up to 3.7 years
  4. Phase II Group 4: Number of Participants With Dose Reductions and Dose Interruptions of INC280 and EGF618Time frame: From start of treatment until end of treatment, assessed up to 3.6 years
  5. Phase II Group 4: Dose IntensityTime frame: From start of treatment until end of treatment, assessed up to 3.6 years
  6. Phase II Group 5: ORR Per RECIST 1.1 Based on Investigator's Assessment for INC280 MonotherapyTime frame: Up to approximately 3 years (while on INC280 monotherapy)

Locations

19 sites in 11 countries. Site status is shown where the registry gives one.

  • Massachusetts General Hospital Mass General

    Boston, Massachusetts

  • Novartis Investigative Site

    Melbourne, Victoria, Australia

  • Novartis Investigative Site

    Edmonton, Alberta, Canada

  • Novartis Investigative Site

    Marseille, France

  • Novartis Investigative Site

    Heidelberg, Baden-Wurttemberg, Germany

  • Novartis Investigative Site

    Cologne, North Rhine-Westphalia, Germany

  • Novartis Investigative Site

    Bologna, BO, Italy

  • Novartis Investigative Site

    Modena, MO, Italy

  • Novartis Investigative Site

    Perugia, PG, Italy

  • Novartis Investigative Site

    Oslo, Norway

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Seoul, Korea, South Korea

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain

  • Novartis Investigative Site

    A Coruña, Galicia, Spain

  • Novartis Investigative Site

    Las Palmas de Gran Canarias, Las Palmas de Gran Canaria, Spain

  • Novartis Investigative Site

    Taipei, Taiwan ROC, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.